Immunovia to Host a Third Webinar in the Series on IMMray™ PanCan-d: Verification Study and Clinical Use
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, today announced that the company will be hosting the third webinar in the series on IMMray™ PanCan-d, Immunovia´s test for early detection of pancreatic cancer. This third webinar will cover IMMray™PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3: